Prof. PeptideProf. Peptide
Guide

Survodutide Dosage in 2026: Trial Doses and What Clinics Report

Survodutide (BI 456906) is Boehringer Ingelheim's investigational once-weekly injection that activates the glucagon and GLP-1 receptors. Its peer-reviewed phase 3 SYNCHRONIZE trials gave 3,600 or 6,000 mcg (3.6 or 6.0 mg) once weekly [1][2][3]; clinics that discuss it quote those doses rather than a protocol of their own [7][8]. It is not approved anywhere.

No approved dose

Survodutide has no FDA approval, no prescribing information and no label. The doses below are what its trials administered and what clinics report, as their sources state them [1][7].

How is survodutide dosed?

Survodutide is dosed once weekly by subcutaneous injection, raised gradually over an extended period to limit side effects, to 3,600 or 6,000 mcg (3.6 or 6.0 mg) in its phase 3 trials [1][7]. Clinics that discuss survodutide quote those trial doses rather than a protocol of their own [7][8]. No trial has set a dose for use outside a study.

  • Clinics: no clinic was found prescribing survodutide after searching 13 clinic sources, the eight largest telehealth companies among them; clinics describe it as available only inside clinical trials [7][8].
  • What clinics quote: the phase 3 doses of 3,600 and 6,000 mcg (3.6 and 6.0 mg) weekly [7][8], or, on pages that predate phase 3, the phase 2 range of 600 to 4,800 mcg (4.8 mg) [9].
  • The weight figure clinics quote varies with the analysis: one quotes 16.6% at 6,000 mcg (6 mg), the completers figure, and another 13.0%, the journal's treatment-regimen result [1][7][8].
  • Frequency: once weekly in every source. No clinic publishes a step schedule, maximum dose or course length of its own [7][8][9].

The side effects are under What are the side effects of survodutide at each dose?, its legal status under Is survodutide legal?, and each trial’s doses under What do human studies show about survodutide dosing?

How is survodutide taken?

Survodutide was administered as a once-weekly subcutaneous injection in every published trial, with the dose raised step by step to the maintenance dose; in phase 3 the dose was adjusted up to 3,600 or 6,000 mcg (3.6 or 6.0 mg) [1][2]. Two formulation studies in healthy people compare a pre-filled syringe with a pen-like injector [10].

No approved label sets a missed-dose rule. The GLP-1 dose calculator converts a dose to syringe units for any concentration; it does not set a dose.

What are the side effects of survodutide at each dose?

Survodutide's side effects in its trials were mainly gastrointestinal: in the phase 3 obesity trial they affected 80.9% and 89.7% at 3,600 and 6,000 mcg (3.6 and 6.0 mg) vs 47.9% on placebo, typically mild to moderate, with no deaths [1]; in type 2 diabetes, 72.8% and 77.7% vs 38.6% [2]. No label lists contraindications.

  • Fatty liver trial (phase 3): gastrointestinal events were the most frequent, commonly during dose escalation and generally mild to moderate [3].
  • Phase 2 MASH trial: nausea 66% vs 23%, diarrhea 49% vs 23% and vomiting 41% vs 4% on placebo, with serious adverse events in 8% vs 7% [5].
  • Phase 2 obesity trial: adverse events in 91% vs 75%, gastrointestinal in 75% vs 42%; about 60% completed treatment, similar on survodutide and placebo [4].
  • Type 2 diabetes trial: adverse events in 77.8% vs 52.5% on placebo and 52.0% on semaglutide; the authors suggest slower dose escalation may reduce them [6].

What clinics report

Clinics describe the trial picture, gastrointestinal effects such as nausea, vomiting, diarrhea and constipation shared with other GLP-1 drugs, and report none of their own patients [7][8]. Phase 3 rates for heart rate, liver enzymes and serious adverse events are not in the abstracts read [1][2][3].

What do human studies show about survodutide dosing?

Survodutide's doses have been tested in randomized trials: three peer-reviewed phase 3 trials in 2026, in obesity, obesity with type 2 diabetes and fatty liver disease, used 3,600 and 6,000 mcg (3.6 and 6.0 mg) once weekly [1][2][3], after phase 2 trials of 600 to 6,000 mcg (6 mg) in obesity, MASH and type 2 diabetes [4][5][6].

No published phase 3 trial compares it with another obesity drug; the phase 2 type 2 diabetes trial included open-label semaglutide [6]. The phase 3 abstracts give no step-by-step escalation schedule [1][2].

SYNCHRONIZE-1 — obesity without diabetes

NCT06066515

N Engl J Med 2026 [1]

Doses: 725 adults (241, 242 and 242) randomized to survodutide adjusted up to 3,600 or 6,000 mcg (3.6 or 6.0 mg) once weekly by subcutaneous injection, or placebo, with lifestyle counseling, for 76 weeks [1].

Result: Weight change −12.2% and −13.0% vs −5.4% on placebo (treatment-regimen analysis); at least 5% weight loss in 72.6% and 71.9% vs 46.3% [1].

Safety: Gastrointestinal adverse events in 80.9% and 89.7% vs 47.9% on placebo, typically mild to moderate, with no deaths [1].

SYNCHRONIZE-2 — obesity with type 2 diabetes

NCT06066528

N Engl J Med 2026 [2]

Doses: 752 adults (250, 251 and 251), mean age 55.7, mean BMI 36.5, randomized to 3,600 or 6,000 mcg (3.6 or 6.0 mg) once weekly or placebo for 76 weeks [2].

Result: Weight change −8.2% and −9.8% vs −3.9% on placebo; at least 5% weight loss in 57.6% and 64.5% vs 35.1% [2].

Safety: Gastrointestinal adverse events in 72.8% and 77.7% vs 38.6% on placebo [2].

SYNCHRONIZE-MASLD — obesity with fatty liver disease

Nat Med 2026 [3]

Doses: 216 adults randomized 2:1 to 6,000 mcg (6.0 mg) once weekly (146) or placebo (70) for 48 weeks, in the US and Spain [3].

Result: Liver fat fell by at least 30% in 84.2% vs 24.3% on placebo (efficacy analysis; 68.5% vs 28.6% by treatment regimen); weight −8.7% vs −1.4% by treatment regimen [3].

Safety: Gastrointestinal events were the most frequent, commonly during dose escalation and generally mild to moderate [3].

Phase 2 — obesity

Lancet Diabetes Endocrinol 2024 [4]

Doses: 387 adults, 600 to 4,800 mcg (4.8 mg) once weekly or placebo for 46 weeks [4].

Result: Weight change up to −14.9% at 4,800 mcg (4.8 mg) vs −2.8% on placebo; a correction to the paper was published in 2026 [4].

Safety: Adverse events in 91% vs 75% on placebo, gastrointestinal in 75% vs 42%; about 60% completed the 46-week treatment period, similar on survodutide and placebo [4].

Phase 2 — MASH with fibrosis

N Engl J Med 2024 [5]

Doses: 293 people with MASH and fibrosis, 2,400 to 6,000 mcg (2.4–6.0 mg) once weekly or placebo [5].

Result: MASH improved in up to 62% vs 14% on placebo [5].

Safety: Nausea 66% vs 23%, diarrhea 49% vs 23% and vomiting 41% vs 4%; serious adverse events 8% vs 7% [5].

Phase 2 — type 2 diabetes

Diabetologia 2024 [6]

Doses: Weekly survodutide at a range of doses against placebo and open-label semaglutide [6].

Result: HbA1c fell by 0.91 to 1.71 points at 16 weeks [6].

Safety: Adverse events in 77.8% on survodutide, mainly gastrointestinal, vs 52.5% on placebo and 52.0% on semaglutide; the authors suggest slower dose escalation may reduce them [6].

FAQ

What is the dosage of survodutide?
Survodutide has no approved dose. Its phase 3 SYNCHRONIZE trials gave 3,600 or 6,000 mcg (3.6 or 6.0 mg) once weekly by subcutaneous injection, raised gradually to limit side effects. Clinics that discuss it quote those trial doses rather than a protocol of their own, and none was found prescribing it.
How much weight do people lose on survodutide?
In SYNCHRONIZE-1, adults with obesity without diabetes changed weight by −12.2% and −13.0% at 3,600 and 6,000 mcg (3.6 and 6.0 mg) vs −5.4% on placebo over 76 weeks. The 16.6% some clinics quote counts only participants who completed treatment; with type 2 diabetes the changes were −8.2% and −9.8%.
How often is survodutide dosed?
Once weekly, in every published trial: a subcutaneous injection raised step by step over an extended period to the 3,600 or 6,000 mcg (3.6 or 6.0 mg) maintenance dose in phase 3. Clinics describe the same weekly schedule. No approved label sets a missed-dose rule or a course length.
What are the side effects of survodutide?
Mainly gastrointestinal: in the phase 3 obesity trial they affected 80.9% and 89.7% at 3,600 and 6,000 mcg (3.6 and 6.0 mg) vs 47.9% on placebo, typically mild to moderate and most common during dose escalation. In type 2 diabetes the rates were 72.8% and 77.7% vs 38.6%.
Is survodutide approved or legal to prescribe?
No. Survodutide is investigational and not approved in any country; clinics describe it as available only inside clinical trials. It is on neither of FDA's bulk lists for compounding and is not part of an approved drug. Research-grade survodutide is sold for laboratory research use only.

References

  1. le Roux CW, Wharton S, Startseva E, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1). N Engl J Med. Published June 7, 2026. PMID 42253238. NCT06066515. https://pubmed.ncbi.nlm.nih.gov/42253238/
  2. Wharton S, le Roux CW, Startseva E, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes (SYNCHRONIZE-2). N Engl J Med. Published October 1, 2026. PMID 42820639. NCT06066528. https://pubmed.ncbi.nlm.nih.gov/42820639/
  3. Kaplan LM, Startseva E, le Roux CW, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease (SYNCHRONIZE-MASLD). Nat Med. Published June 7, 2026. PMID 42252333. https://pubmed.ncbi.nlm.nih.gov/42252333/
  4. le Roux CW, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12:162–73. PMID 38330987; correction 2026, PMID 41421369. https://pubmed.ncbi.nlm.nih.gov/38330987/
  5. Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024. PMID 38847460. https://pubmed.ncbi.nlm.nih.gov/38847460/
  6. Blüher M, et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes. Diabetologia. 2024. PMID 38095657. https://pubmed.ncbi.nlm.nih.gov/38095657/
  7. Second Nature (US); medically reviewed; last updated November 2026; read November 5, 2026. Cited for its description of the trial schedule, its completers figure and its filing statement. https://www.secondnature.io/us/guides/current-health/survodutide-weight-loss-phase-3
  8. PepScribe, updated October 27, 2026; read November 5, 2026. Cited for its quotation of the phase 3 dose and result. https://pepscribe.com/learn/survodutide-vs-tirzepatide-reddit
  9. SimplyMeds Online (UK pharmacy). Read November 4, 2026. Cited for its status statement and its phase 2 dose range. https://www.simplymedsonline.co.uk/pages/survodutide-the-next-generation-of-dual-hormone-weight-loss.html
  10. ClinicalTrials.gov. NCT07413913 and NCT07768813: formulation studies (pre-filled syringe vs pen-like injector) in healthy people, as listed in Prof. Peptide’s research-lane search, November 5, 2026. https://clinicaltrials.gov/study/NCT07413913
  11. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  12. U.S. Food and Drug Administration. 503B Bulk Drug Substances List. https://www.fda.gov/drugs/human-drug-compounding/503b-bulk-drug-substances-list
  13. U.S. Food and Drug Administration. Warning Letter: GLP-1 Solution, reference 715883, September 9, 2025 (names retatrutide; does not name survodutide). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025
  14. TrimRX, survodutide cost breakdown, May 2026; read November 4, 2026. Cited for its approval-timing statement. https://trimrx.com/blog/?p=90677
  15. World Anti-Doping Agency. The Prohibited List (2026). Valid January 1, 2026. https://www.wada-ama.org/en/prohibited-list

Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.

Checked and updated